VENUE



PARANIMF DE LA FACULTAT DE MEDICINA DE LA UB

Carrer de Casanova, 143, 08036 Barcelona

An application has been made to the UEMS EACCME® for CME/CPD accreditation of this event

TECHNICAL SECRETARIAT

Mar Alcoverro
Tel. 93 203 23 31
maralcoverro@academia.cat

L'Acadèmia
Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i de Balears dona suport als Objectius de Desenvolupament Sostenible

SPONSORS

Gold sponsor

AstraZeneca

Silver sponsors

Eisai

Bronze sponsor

Boston Scientific
Advancing science for life™

Guerbet

Others

Bristol Myers Squibb®


Roche

TERUMO

BCLC 2026 Update

Liver Cancer Decisions Across Regions

How BCLC and CUSE are applied, adapted, and debated worldwide



Paranimf, Faculty of Medicine, University of Barcelona

16th - 17th November 2026

In-person, virtual and on-demand

Director: Dr. María Reig

L'Acadèmia
Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i de Balears dona suport als Objectius de Desenvolupament Sostenible

BCLC Barcelona Clinic Liver Cancer

IDIBAPS Institut d'Investigacions Biomèdiques August Pi i Sunyer

ciber EHD

Clínic Barcelona

Universitat de Barcelona
Càtedra de Càncer de Fetge

AstraZeneca

Roche

BCLC 2026 Update - Liver Cancer Decisions Across Regions

16th November 2026

- 11:30-12:25
Registration & Networking Lunch

- 12:25-12:30
Opening
María Reig

- 12:30-13:10
Evidence Snapshots: Diagnosis & Staging Worldwide—Convergence and Divergence
Chairs: Jordi Rimola (Spain) and Alba Díaz (Spain)
Presentations:
- **Pathology perspective:** Valérie Paradis (France)
- **Radiology perspective:** Hanyu Jiang (China)

Debate: Fabio Piscaglia (Italy), Victoria Chernyak (USA)

- 13:10-13:50
Evidence Snapshots (HCC): What is the Recommended Treatment for 2026?
Chairs: Marco Sanduzzi (Spain) and Mohamed AbdAllah (Egypt)
Presentation: Leonardo da Fonseca (Brazil)
Debate: Massimo Iavarone (Italy), Hui Chuan Sun (China), Jean-Charles Nault (France)

- 13:50-14:30
Evidence Snapshots (CCA): What is the Recommended Strategy for 2026?
Chairs: Teresa Macarulla (Spain) and Grainne O'Kane (Ireland)
Presentation: Alejandro Forner (Spain)
Debate: Stephen Chan (Hong Kong), Leonardo da Fonseca (Brazil), Elisabeth Baucells (ATUVIBI)

- 14:30-15:15 Coffee break

- 15:15-16:00
Multi-omics and AI in Liver Cancer: From Data to Decisions
Chairs: Montserrat Marí (Spain) and Manon Allaire (France)

- 15:15-15:20 – Flash Talk: Multi-omics
Josep Maria Argemí (Spain)
- 15:20-15:25 – Flash Talk: AI and Compliance
Jordi Albó (USA)
- 15:25-16:00 – Discussion

Debate: Marta Puyol (FC-AECC), Marta Iglesias (ASARGA), Fernando Rotellar (Spain), Sherrie Bhoori (Italy)

- 16:00-17:00
Local Choices (HCC): Applying Evidence When Reality Pushes Back
Chairs: Bruno Sangro (Spain) and Neus Llarch (Spain)
Clinical Scenarios: Marta Fortuny (Spain), Víctor Holguín (Spain), Ernest Belmonte (Spain)
Panelists: Vincenzo Mazzaferro (Italy), Riad Salem (USA), Stephen Chan (Hong Kong), Marta Burrel (Spain)

- 17:00-17:15
Day 1 Key Takeaways
Marta Fortuny (Spain) and Mario Matute (Spain)

17th November 2026

- 9:00-9:30
Enhancing Humans, Engineering Them, or Causing Harm? The Consequences of AI Design at a Human Crossroads
Chair: María Reig (Spain)
Presentation: Jordi Albó (USA)

- 9:30-10:00
Liver Transplantation or Not for Intermediate HCC? When and Why
Chairs: Vincenzo Mazzaferro (Italy) and Joana Ferrer (Spain)
Introduction: Marco Sanduzzi (Spain)
Debate: Fernando Rotellar (Spain), Ernest Hidalgo (Spain), Hui Chuan Sun (China)

- 10:00-10:30
Systemic Treatment for Intermediate HCC: When to Treat—and When Not To
Chairs: Jordi Bruix (Spain) and Riad Salem (USA)
Introduction: Marco Sanduzzi (Spain)
Debate: Peter Galle (Germany), Irene Bargellini (Italy), Jordi Rimola (Spain)

- 10:30-11:10 Coffee break

- 11:10-12:00
HCC Sequencing After First-Line Therapy: Regional Strategies and Practical Choices
Chairs: Bruno Sangro (Spain) and Lorenza Rimassa (Italy)
Presentation: María Reig (Spain)
Debate: Grainne O'Kane (Ireland), Stephen Chan (Hong Kong)

- 12:00-12:45
Radiologists in the Hot Seat: Vascular Invasion and Other Decision-Makers
Chairs: Maxime Ronot (France) and Hanyu Jiang (China)
Introduction: Assessment of Vascular Invasion: How Can We Minimize Subjectivity? Mario Matute (Spain)
Debate: Anna Darnell (Spain), Victoria Chernyak (USA)

- 12:45-13:30
MetALD/MASLD Management: What We Agree On—and What We Don't
Chairs: Fabio Piscaglia (Italy) and Jordi Rimola (Spain)
Presentations:
- **Where Screening Fails and How to Fix It:** Maxime Ronot (France)
- **New Rules for Screening and Treatment Pathways:** Marco Sanduzzi (Spain)
- **Pathology/Molecular Signals with Clinical Impact:** Valérie Paradis (France)

Panelists: Mohamed AbdAllah (Egypt), Hanyu Jiang (China)

- 13:30-14:30
CUSE in Practice: How the World Decides in HCC (BCLC 0/A, BCLC B and BCLC C)
Chairs: Marta Fortuny (Spain) and Stephen Chan (Hong Kong)
Clinical Scenarios: Mario Matute (Spain), Gemma Iserte (Spain)
Debate 1: Manon Allaire (France), Takahiro Kodama (Japan), Ignacio Marín (Colombia)
Debate 2: Sherrie Bhoori (Italy), Gonzalo Sapisochin (Spain), Anna Darnell (Spain)
Debate 3: Tamer El-Baz (Egypt), Hui Chuan Sun (China), Joana Ferrer (Spain)

- 14:30-14:45
Closing Remarks
María Reig (Spain) and Marco Sanduzzi (Spain)

- 14:45 Lunch Buffet